Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04485130 · ClinicalTrials.gov registry record · Phase 2
DISulfiram for COvid-19 (DISCO) Trial
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04485130 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 11 participants.
The verdict
NCT04485130, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Disulfiram (DSF) a safe, easily dosed, FDA-approved drug for the treatment of alcohol dependence has been identified to be a potential therapeutic target for SARS-CoV-2 infection. Disulfiram may have both antiviral (inhibiting viral replication via blocking the Mpro protease and zinc ejection) and anti-inflammatory effects (via inhibition of NF-kB-induced and NLRP inflammasome-induced cytokine release) on SARS-CoV-2. We will study oral disulfiram given for 5 consecutive days (1000 mg/day in cohort 1; 2000 mg/day in cohort 2) in 60 symptomatic COVID+ individuals in a randomized (2:1) randomized, double blind placebo-controlled trial evaluating disulfiram's effect on COVID-19 symptom severity, SARS-CoV-2 viral load, and biomarkers of inflammation and pyroptosis (aberrant pro-inflammatory cell death) over 31 days.
Interventions
- DRUG Placebo
- DRUG Disulfiram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-08-18 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04485130
The ClinicalTrials.gov registry entry for NCT04485130 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04485130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04485130 about?
NCT04485130 is a clinical study titled "DISulfiram for COvid-19 (DISCO) Trial". Disulfiram (DSF) a safe, easily dosed, FDA-approved drug for the treatment of alcohol dependence has been identified to be a potential therapeutic target for SARS-CoV-2 infection. Disulfiram may have both antiviral (inhibiting viral replication via blocking the Mpro protease and zinc ejection) and a...
What is the current status of trial NCT04485130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2021-08-18. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT04485130?
The interventions under investigation include: Placebo (DRUG), Disulfiram (DRUG).
Who is sponsoring clinical trial NCT04485130?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.